---
title: "周一股市最大变动者：VALN、KDP、加密货币股票及其他"
description: "随着华尔街进入八月最后一个交易周，股票期货小幅下跌，市场关注 Nvidia 的财报。值得注意的股票动向包括 scPharmaceuticals（SCPH），在 MannKind（MNKD）达成高达 3.6 亿美元的收购协议后上涨了 13%"
type: "news"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/254465903.md"
published_at: "2025-08-25T13:44:43.000Z"
---

# 周一股市最大变动者：VALN、KDP、加密货币股票及其他

> 随着华尔街进入八月最后一个交易周，股票期货小幅下跌，市场关注 Nvidia 的财报。值得注意的股票动向包括 scPharmaceuticals（SCPH），在 MannKind（MNKD）达成高达 3.6 亿美元的收购协议后上涨了 13%

Stock futures edged lower on Monday as Wall Street kicked off the final trading week of August with focus on Nvidia’s upcoming earnings. Here are some of Monday's biggest stock movers: Biggest stock gainers scPharmaceuticals (SCPH) +13% - Shares surged after MannKind (MNKD) agreed to acquire the company in a deal valued at up to $360M. MNKD will pa...

### Related Stocks

- [SCPH.US - Scpharmaceuticals](https://longbridge.com/zh-CN/quote/SCPH.US.md)
- [MNKD.US - 曼恩凯德生物医疗](https://longbridge.com/zh-CN/quote/MNKD.US.md)
- [NVDA.US - 英伟达](https://longbridge.com/zh-CN/quote/NVDA.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Top Picks 2026: MannKind Corp. | MannKind Corp. (MNKD) is highlighted as a top pick for 2026 due to its progress in 2025, particularly with its inhalable | [Link](https://longbridge.com/zh-CN/news/275985463.md) |
| FDA prüft Zulassung von Afrezza Inhalationsinsulin für Kinder und Jugendliche | The FDA has accepted a supplemental Biologics License Application (sBLA) for Afrezza inhalation powder for children and  | [Link](https://longbridge.com/zh-CN/news/275305828.md) |
| How 2026 FDA Decisions on Afrezza and FUROSCIX At MannKind (MNKD) Have Changed Its Investment Story | MannKind Corporation has outlined key regulatory milestones, including anticipated 2026 FDA decisions on Afrezza and FUR | [Link](https://longbridge.com/zh-CN/news/272157412.md) |
| Stuart A. Tross, Chief People & Workplace Officer, Reports Disposal of MannKind Corporation Common Shares | Stuart A. Tross, Chief People & Workplace Officer of MannKind Corporation, has reported the disposal of common shares of | [Link](https://longbridge.com/zh-CN/news/272136429.md) |
| MannKind Reports Record Q4 Revenue and Highlights 2026 Growth Drivers | MannKind Corporation reported record Q4 revenue exceeding $100 million and highlighted its acquisition of scPharmaceutic | [Link](https://longbridge.com/zh-CN/news/271937147.md) |

---

> **免责声明**：本文内容仅供参考，不构成任何投资建议。